Patents by Inventor Hermut WEHLAN

Hermut WEHLAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10696633
    Abstract: A new process for the preparation of fexofenadine and of related intermediates, which can be used in the preparation of fexofenadine, is provided.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: June 30, 2020
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hermut Wehlan, Kai Rossen, Guenter Billen
  • Patent number: 10336698
    Abstract: A new process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile is described. This compound can be used for the production of drugs, such as Fexofenadine.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: July 2, 2019
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hermut Wehlan, Kai Rossen, Alexander Schaefer
  • Publication number: 20180297951
    Abstract: A new process for the preparation of fexofenadine and of related intermediates, which can be used in the preparation of fexofenadine, is provided.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 18, 2018
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hermut WEHLAN, Kai ROSSEN, Guenter BILLEN
  • Publication number: 20170369440
    Abstract: A new process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile is described. This compound can be used for the production of drugs, such as Fexofenadine.
    Type: Application
    Filed: January 21, 2016
    Publication date: December 28, 2017
    Inventors: Hermut WEHLAN, Kai ROSSEN, Alexander SCHAEFER
  • Patent number: 9834527
    Abstract: The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: December 5, 2017
    Assignee: SANOFI
    Inventors: Andreas Evers, Christopher Kallus, Michael Wagner, Hermut Wehlan
  • Publication number: 20160137618
    Abstract: The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments.
    Type: Application
    Filed: June 5, 2014
    Publication date: May 19, 2016
    Inventors: Andreas Evers, Christopher Kallus, Michael Wagner, Hermut Wehlan
  • Patent number: 9199947
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 1, 2015
    Assignee: Sanofi
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Patent number: 9156815
    Abstract: The invention relates to the salt of naphthalene-1,5-disulfonic acid with (R)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)ethyl propionate, which can be represented by the following structural formula of formula (I), to methods for the production thereof, to drugs containing said salt, and to the use of said drugs to treat diseases that are accompanied by thromboses, embolisms, hypercoagulability, or fibrotic changes.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: October 13, 2015
    Assignee: Sanofi
    Inventors: Kai Rossen, Hermut Wehlan
  • Patent number: 9150526
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: October 6, 2015
    Assignee: Sanofi
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Publication number: 20140336226
    Abstract: The invention relates to the salt of naphthalene-1,5-disulfonic acid with (R)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)ethyl propionate, which can be represented by the following structural formula of formula (I), to methods for the production thereof, to drugs containing said salt, and to the use of said drugs to treat diseases that are accompanied by thromboses, embolisms, hypercoagulability, or fibrotic changes.
    Type: Application
    Filed: November 22, 2012
    Publication date: November 13, 2014
    Inventors: Kai Rossen, Hermut Wehlan
  • Patent number: 8865906
    Abstract: The present invention relates to a process for the preparation of a compound of the formula I, which comprises reacting a compound of the formula IV with an oxalic acid diester and to novel intermediate compounds used therein.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: October 21, 2014
    Assignee: Sanofi
    Inventors: Kai Rossen, Volker Kraft, Hermut Wehlan, Antony Bigot, Veronique Crocq-Stuerga
  • Publication number: 20140296239
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: SANOFI
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Publication number: 20140296296
    Abstract: The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Inventors: Sven Ruf, Thorsten Sadowski, Klaus Wirth, Herman Schreuder, Christian Buning, Christopher Kallus, Hartmut Strobel, Hermut Wehlan
  • Patent number: 8716481
    Abstract: The present invention relates to a process for making 6-substituted-1-(2H)-isoquinolinone derivatives of formula (I) wherein R1 and n are as described in the specification. The present invention further relates to novel intermediates which are used in the process according to the invention and to processes for preparing such intermediates.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: May 6, 2014
    Assignee: Sanofi
    Inventors: Kai Rossen, Hermut Wehlan, Oliver Plettenburg, Volker Kraft, Guenter Billen, Simon Gessler
  • Publication number: 20120264925
    Abstract: A process for preparing pyrazole-glycoside derivatives of the general Formula (I) in which the meanings are R1 H and R2 F; or R1 F and R2 H; or R1 F and R2 F; R3 (C1-C8)-alkyl, where one, more than one or all hydrogen(s) may be replaced by fluorine; X (C1-C3)-alkylene, (C2-C3)-alkenylene.
    Type: Application
    Filed: August 26, 2010
    Publication date: October 18, 2012
    Applicant: SANOFI
    Inventors: Michael Podeschwa, David Rigal, Kai Rossen, Bernhard Otto, Hermut Wehlan, Theodor Andreas Wollmann, Bernd Becker, Berndt Kulitzscher, Alexander Schaefer
  • Publication number: 20120245358
    Abstract: The present invention relates to a process for the preparation of a compound of the formula I, which comprises reacting a compound of the formula IV with an oxalic acid diester and to novel intermediate compounds used therein.
    Type: Application
    Filed: May 11, 2010
    Publication date: September 27, 2012
    Applicant: SANOFI
    Inventors: Kai Rossen, Volker Kraft, Hermut Wehlan, Antony Bigot, Veronique Crocq-Stuerga
  • Publication number: 20110021779
    Abstract: The present invention relates to a process for making 6-substituted-1-(2H)-isoquinolinone derivatives of formula (I) wherein R1 and n are as described in the specification. The present invention further relates to novel intermediates which are used in the process according to the invention and to processes for preparing such intermediates.
    Type: Application
    Filed: June 17, 2010
    Publication date: January 27, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Kai ROSSEN, Hermut WEHLAN, Oliver PLETTENBURG, Volker KRAFT, Guenter BILLEN, Simon GESSLER